Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760263 · ClinicalTrials.gov registry record · Phase 4
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
A Phase 4 study of Transplant;Failure,Kidney, sponsored by Sentara Norfolk General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03760263 is a Phase 4 study of Transplant;Failure,Kidney that has completed, run by Sentara Norfolk General Hospital. The registered enrollment target is 46 participants, below the 82-participant average among 5 other Transplant;Failure,Kidney trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03760263, a Phase 4 study of Transplant;Failure,Kidney, has completed, sponsored by Sentara Norfolk General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
Conditions Studied
Interventions
- DRUG Tacrolimus
Study Locations (1)
Virginia
- Sentara Norfolk General Hospital - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760263
The ClinicalTrials.gov registry entry for NCT03760263 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 5 other Transplant;Failure,Kidney trials with a reported enrollment target (44% lower). The listed sponsor is Sentara Norfolk General Hospital, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transplant;Failure,Kidney appearing as the primary indexed condition, and to 1 intervention - of which Tacrolimus is the first listed.
NCT03760263 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03760263 about?
NCT03760263 is a clinical study titled "Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus". Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
What is the current status of trial NCT03760263?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2020-01-16. Estimated completion is 2023-11-01.
What conditions does trial NCT03760263 study?
This clinical trial studies the following conditions: Transplant;Failure,Kidney.
What interventions are being tested in trial NCT03760263?
The interventions under investigation include: Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT03760263?
This trial is sponsored by Sentara Norfolk General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03760263 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplant;Failure,Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
RECRUITING · Phase 4
-
Abdominal Wall Transplant
RECRUITING · NA
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
-
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
RECRUITING · NA
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.